Ocular Therapeutix (OCUL) Research & Development (2016 - 2025)
Historic Research & Development for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $50.8 million.
- Ocular Therapeutix's Research & Development rose 2393.57% to $50.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $197.1 million, marking a year-over-year increase of 5442.16%. This contributed to the annual value of $197.1 million for FY2025, which is 5442.16% up from last year.
- Per Ocular Therapeutix's latest filing, its Research & Development stood at $50.8 million for Q4 2025, which was up 2393.57% from $52.4 million recorded in Q3 2025.
- In the past 5 years, Ocular Therapeutix's Research & Development ranged from a high of $52.4 million in Q3 2025 and a low of $10.9 million during Q1 2021
- Moreover, its 5-year median value for Research & Development was $15.1 million (2023), whereas its average is $24.5 million.
- Per our database at Business Quant, Ocular Therapeutix's Research & Development crashed by 547.66% in 2022 and then soared by 15309.66% in 2024.
- Quarter analysis of 5 years shows Ocular Therapeutix's Research & Development stood at $12.6 million in 2021, then grew by 7.67% to $13.5 million in 2022, then rose by 19.58% to $16.2 million in 2023, then soared by 153.1% to $41.0 million in 2024, then grew by 23.94% to $50.8 million in 2025.
- Its Research & Development was $50.8 million in Q4 2025, compared to $52.4 million in Q3 2025 and $51.1 million in Q2 2025.